Aviceda Therapeutics is winding down operations after a Phase 2 failure, according to a source familiar with the decision. The biotech had planned to advance an eye drug into Phase 3 despite the mid-stage clinical setback. A shutdown after a Phase 2 miss typically compresses timelines for asset development, leaving remaining IP and any potential out-licensing pathways as the primary strategic options. For investors and collaborators, the development underscores how quickly capital formation and program continuity can turn when late preclinical or early clinical assumptions do not translate. The company’s exit is a reminder for ophthalmology developers relying on narrow clinical windows—especially where trial outcomes may determine whether programs can raise follow-on financing or find partners for Phase 3 execution.